Ignite Creation Date:
2024-05-06 @ 3:20 AM
Last Modification Date:
2024-10-26 @ 11:32 AM
Study NCT ID:
NCT02264665
Status:
COMPLETED
Last Update Posted:
2023-11-13
First Post:
2014-09-02
Brief Title:
OPALINE A Study Of Morbidity And Mortality At 2 Years
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
AN OBSERVATIONAL REAL-WORLD STUDY OF THE SYSTEMIC TREATMENT OF WELL-DIFFERENTIATED UNRESECTABLE OR METASTATIC PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOURS PNET A STUDY OF MORBIDITY AND MORTALITY AT 2 YEARS
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OPALINE
Brief Summary:
A descriptive prospective partly retrospective multisite observational study conducted in France in adult patients treated for a well differentiated unresectable or metastatic pancreatic neuroendocrine tumor with disease progression
Detailed Description:
prospective and retrospective Analyses will be performed using SAS software
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| OPALINE | OTHER | Alias Study Number | None |